Inventor · disambiguated record
Thomas A. Dineen
Also filed as: DINEEN JR THOMAS A · DINEEN THOMAS · DINEEN THOMAS A
26 granted patents·14 pending applications·109 citations·filing 2008–2024
94Inventor score
Top patents by PatentIndex Score
40 records- 0194US11534441B2MAP4K1 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2021·Granted Dec 27, 2022·3 cites·25 claims
- 0294US10829493B2Compositions and methods for treating KIT- and PDGFRA-mediated diseasesBLUEPRINT MEDICINES CORP·Filed 2020·Granted Nov 10, 2020·5 cites·41 claims
- 0394US8426447B2Spiro-tricyclic ring compounds as beta-secretase modulators and methods of useWHITE RYAN·Filed 2009·Granted Apr 23, 2013·58 cites·22 claims
- 0493US11718602B2EGFR inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Aug 8, 2023·2 cites·8 claims
- 0590US12042495B2MAP4K1 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Jul 23, 2024·1 cites·18 claims
- 0687US10383866B2Alkyl dihydroquinoline sulfonamide compoundsAMGEN INC·Filed 2016·Granted Aug 20, 2019·3 cites·37 claims
- 0782US10729684B2Alkynyl dihydroquinoline sulfonamide compoundsAMGEN INC·Filed 2016·Granted Aug 4, 2020·3 cites·20 claims
- 0882US10167279B2Compounds and compositions as RAF kinase inhibitorsNOVARTIS AG·Filed 2015·Granted Jan 1, 2019·3 cites·17 claims
- 0981US9776995B2Bicyclic sulfonamide compounds as sodium channel inhibitorsAMGEN INC·Filed 2014·Granted Oct 3, 2017·4 cites·24 claims
- 1080US9012443B2Bicyclic aryl and heteroaryl sodium channel inhibitorsAMGEN INC·Filed 2012·Granted Apr 21, 2015·6 cites·32 claims
- 1180US9012446B2Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of useAMGEN INC·Filed 2013·Granted Apr 21, 2015·4 cites·20 claims
- 1280US2025289801A1Egfr inhibitorsBLUEPRINT MEDICINES CORP·Filed 2024·Application pending·0 cites
- 1377US12448379B2Wild type kit inhibitorsBLUEPRINT MEDICINES CORP·Filed 2024·Granted Oct 21, 2025·0 cites·33 claims
- 1477US9212182B2Bicyclic sulfonamide compounds as sodium channel inhibitorsAMGEN INC·Filed 2014·Granted Dec 15, 2015·3 cites·32 claims
- 1576US10472356B2Bicyclic ketone sulfonamide compoundsAMGEN INC·Filed 2016·Granted Nov 12, 2019·3 cites·17 claims
- 1676US9458152B2Bicyclic sulfonamide compounds as sodium channel inhibitorsAMGEN INC·Filed 2015·Granted Oct 4, 2016·2 cites·18 claims
- 1776US8883782B2Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of useCHENG YUAN·Filed 2011·Granted Nov 11, 2014·4 cites·18 claims
- 1873US9346827B25-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of useDINEEN THOMAS·Filed 2012·Granted May 24, 2016·2 cites·14 claims
- 1972US12172983B2EGFR inhibitorsBLUEPRINT MEDICINES CORP·Filed 2021·Granted Dec 24, 2024·0 cites·21 claims
- 2071US9051311B2Sulfamide sodium channel inhibitorsAMGEN INC·Filed 2013·Granted Jun 9, 2015·1 cites·20 claims
- 2170US10377770B2Tricyclic compounds and compositions as kinase inhibitorsNOVARTIS AG·Filed 2016·Granted Aug 13, 2019·1 cites·30 claims
- 2264US9079902B2Heteroaryl sodium channel inhibitorsDINEEN THOMAS·Filed 2012·Granted Jul 14, 2015·1 cites·19 claims
- 2363US2025092036A1Compounds and compositions for modulating the activity of erkNOVARTIS AG·Filed 2024·Application pending·0 cites
- 2462US2025236608A1Egfr inhibitorsBLUEPRINT MEDICINES CORP·Filed 2023·Application pending·0 cites
- 2561US12202844B2MAP4K1 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Jan 21, 2025·0 cites·30 claims
- 2660US8163909B2Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of useZHONG WENGE·Filed 2008·Granted Apr 24, 2012·0 cites·17 claims
- 2760US2024336630A1Map4k1 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 2860US2025270190A1Kit inhibitorsBLUEPRINT MEDICINES CORP·Filed 2023·Application pending·0 cites
- 2960US2024382483A1Heterocyclic egfr inhibitors for use in the treatment of cancerBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 3059US2020009129A1Alkyl dihydroquinoline sulfonamide compoundsAMGEN INC·Filed 2019·Application pending·0 cites
- 3159US2024199648A1Map4k1 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 3259US2023019732A1Egfr inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 3358US2024299387A1Heterocyclic egfr inhibitors for use in the treatment of cancerBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 3458US2024308981A1Heterocyclic egfr inhibitors for use in the treatment of cancerBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 3558US2024300946A1Egfr inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 3656US8173810B2Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of useZHONG WENGE·Filed 2008·Granted May 8, 2012·0 cites·17 claims
- 3755US2023391780A1Compositions and methods for treating kit- and pdgfra-mediated diseasesBLUEPRINT MEDICINES CORP·Filed 2021·Application pending·0 cites
- 3854US2024010652A1Compositions and methods for treating kit- and pdgfra-mediated diseasesBLUEPRINT MEDICINES CORP·Filed 2021·Application pending·0 cites
- 3946US8552181B2Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of useZHONG WENGE·Filed 2012·Granted Oct 8, 2013·0 cites·12 claims
- 4042US9346798B2Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitorsAMGEN INC·Filed 2013·Granted May 24, 2016·0 cites·19 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →